LTGO · ISSUER CIK 2056611
Latigo Biotherapeutics, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 6 Latigo Biotherapeutics, Inc. insiders reported $5.0M of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Foresite Capital Management V, LLC (10% Owner), with $2.5M.
↗6 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$5.0MInsider buying
$0.00Insider selling
+$5.0MNet open-market
Aug 12, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 202616:13 | Aug 10, 2026 | LTGO | 10% Owner · +5 joint | C · Convert | — | +7,325,962 | 2,350,419 | — | — | ||
| Aug 12, 202608:18 | Aug 10, 2026 | LTGO | 10% Owner | C · Convert | — | +672,778 | 672,788 | +6727780% | — | ||
| Aug 11, 202606:00 | Aug 10, 2026 | LTGO | 10% Owner · +5 joint | C · Convert | — | +12,695,305 | 2,094,813 | — | — | ||
| Aug 10, 202620:21 | Aug 10, 2026 | LTGO | 10% Owner · +5 joint | P · Buy | $18.00 | +140,000 | 2,008,024 | +7% | +$2.5M | -1.4% | -12.1% |
| Aug 10, 202620:21 | Aug 10, 2026 | LTGO | 10% Owner · +5 joint | C · Convert | — | +9,041,328 | 3,414,544 | — | — | ||
| Aug 10, 202620:00 | Aug 10, 2026 | LTGO | Director, 10% Owner | P · Buy | $18.00 | +140,000 | 2,008,024 | +7% | +$2.5M | -1.4% | -12.1% |
| Aug 10, 202620:00 | Aug 10, 2026 | LTGO | Director, 10% Owner | C · Convert | — | +9,041,328 | 3,414,544 | — | — | ||
| Aug 10, 202620:00 | Aug 10, 2026 | LTGO | Director, 10% Owner | C · Convert | — | +12,695,305 | 2,094,813 | — | — |